drugset / Trial / NCT00199381
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
NaSingle-groupOpen-labelTreatment
Summary
This is an, open-label, long-term safety extension for patients in North America who have completed the prior istradefylline study 6002-INT-001.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Istradefylline | Small molecule | 20 mg | Oral |
| Subject | Istradefylline | Small molecule | 40 mg | Oral |